17 completed. 8 Phase 4, 5 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 8 |
| Phase 2 | 5 | Completed 5 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Latanoprost 0.005%: new trials by email Literature Review of Latanoprost 0.005% trials Research Report on Latanoprost 0.005%
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension NCX 470 0.1%, Latanoprost 0.005% - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Nicox Ophthalmics, Inc. | 696 | 2020-11-09 | 2025-09-08 |
| Nailfold Capillary Blood Flow With Latanoprost Bunod Latanoprost 0.005%, Latanoprost bunod 0.024%, Normal saline 0.9% - Glaucoma, Open-Angle | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 47 | 2019-08-15 | 2021-09-29 |
| Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension NCX 470, Latanoprost 0.005% - Glaucoma, Open-Angle, Hypertension, Ocular | Phase 2 | Completed | Nicox Ophthalmics, Inc. | 656 | 2018-08-01 | 2023-06-18 |
| A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension 0.01% RO7058584, 0.1% RO7058584, 1% RO7058584 - Glaucoma, Open-angle, Ocular Hypertension | Phase 1 | Completed | Hoffmann-La Roche | 27 | 2017-10-10 | 2020-03-31 |
| Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma Brimonidine Tartrate, Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops, Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension - Glaucoma, Open-Angle | Phase 4 | Completed | Afyon Kocatepe University Hospital | 96 | 2014-01-01 | 2019-05-29 |
| Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose Monoprost, Lumigan 0.01%, Lumigan 0.03% Unit Dose - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Laboratoires Thea | 379 | 2013-12-01 | 2020-04-02 |
| AL-54478 Proof of Concept Study AL-54478 0.005%, Latanoprost 0.005%, AL-54478 Vehicle - Open-angle Glaucoma (OAG), Ocular Hypertension (OHT) | Phase 2 | Completed | Alcon Research | 64 | 2011-06-01 | 2014-07-31 |
| AR-12286 in Combination With Latanoprost Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5% - Glaucoma, Ocular Hypertension | Phase 2 | Completed | Aerie Pharmaceuticals | 66 | 2011-02-01 | 2014-05-08 |
| An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, latanoprost 0.005% - Glaucoma, Ocular Hypertension | Phase 4 | Completed | Allergan | 148 | 2008-12-01 | 2011-09-21 |
| Comparing Efficacy and Safety of Combigan With Timolol Adjunctive to Xalatan in Glaucoma or Ocular Hypertension Subjects Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%, timolol maleate 0.5%, latanoprost 0.005% - Glaucoma, Ocular Hypertension | Phase 4 | Completed | Allergan | 204 | 2008-07-01 | 2019-04-23 |
| Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure. PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose - Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Pfizer | 318 | 2007-12-11 | 2021-04-30 |
| A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension. PF-03187207, Latanoprost 0.005%, PF-03187207 Vehicle - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Bausch & Lomb Incorporated | 117 | 2007-12-01 | 2020-09-14 |
| Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo latanoprost 0.005%, Placebo - Glaucoma | Completed | University of Miami | 82 | 2006-02-01 | 2014-03-28 | |
| Latanoprost Versus Fotil latanoprost 0.005%, Fotil, placebo - Open-Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Pharmaceutical Research Network | 36 | 2005-05-01 | 2007-10-24 |
| Cosopt Versus Xalatan timolol maleate 0.5%, dorzolamide/timolol maleate fixed combination, latanoprost 0.005% - Open-Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Pharmaceutical Research Network | 2005-04-01 | 2007-01-09 | |
| Effect of Age on Latanoprost 0.005% in Patients With Glaucoma Latanoprost 0.005% - Glaucoma | Phase 4 | Completed | Yale University | 17 | 2005-03-01 | 2012-12-10 |
| A Study of Glaucoma or Ocular Hypertension in Patients Within the United States latanoprost 0.005%, fixed combination latanoprost-timolol, timolol 0.5% - Ocular Hypertension, Glaucoma | Phase 3 | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 418 | 1997-07-01 | 2021-02-18 |
Ocular Hypertension (13) · Glaucoma, Open-Angle (11) · Glaucoma (6)
Allergan (2) · Nicox Ophthalmics, Inc. (2) · Pharmaceutical Research Network (2) · Aerie Pharmaceuticals (1) · Afyon Kocatepe University Hospital (1) · Alcon Research (1) · Bausch & Lomb Incorporated (1) · Hoffmann-La Roche (1) · Icahn School of Medicine at Mount Sinai (1) · Laboratoires Thea (1) · Pfizer (1) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1) · University of Miami (1) · Yale University (1)
United States (12) · Canada (1) · China (1) · France (1) · Japan (1) · Poland (1)
William C. Stewart, MD (2) · Bruce Shields, MD (1) · Christophe Baudouin, Professor (1) · Dariusz Kecik, Professor (1) · David S Greenfield, MD (1) · Jay Mulaney, MD (1) · Ken Harper (1) · Krystyna Czechowisz-Janicka, Professor (1) · Krystyna Pecold, Professor (1) · Nicox Ophthalmics (1) · Nicox Ophthalmics, Inc. (1)